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Strategy With Ezetimibe
and Atorvastatin on
Coronary Plaque
Regression After PCI
PRECISE-IVUSWe read with interest the recent publication in the
Journal by Tsujita et al. (1). Treatment with the
atorvastatin/ezetimibe combination showed greater
coronary plaque regression; statistical analysis was
performed according to previous intravascular
ultrasound (IVUS) studies. Scrutiny of Table 1 reveals
that there was an excess (12%) of current smokers in
the statin monotherapy group (p ¼ 0.056 using the
Fisher exact test). Smoking is a major risk factor for
premature coronary atherosclerosis and acute
coronary syndromes. Might the difference in current
smokers between the 2 groups have affected the
results and thus favored the group receiving
combination lipid-lowering therapy? That said, careful
review of studies using serial IVUS for assessment of
coronary atheroma progression/regression revealed
omission of consideration of current smoking as a key
factor of immediate relevance (2–4).
Thus, smoking is well established as a risk factor
for CAD, and stopping smoking is one of the principal
measures recommended in secondary prevention of
CAD; however, serial IVUS measures of coronary
atheroma in secondary prevention have not to dateconﬁrmed that smoking is associated with disease
progression.
The recent report of Bolorunduro et al. (5) using
virtual histology IVUS showed that cigarette
smoking is associated with a higher burden of
necrotic core in coronary lesions. Because necrotic
core burden has been consistently shown to predict
the presence of vulnerable plaque, these ﬁndings
could suggest that even if smoking is not associated
with coronary plaque progression, cigarette smoking
increases vulnerable plaque burden and thus the
potential for acute clinical coronary syndromes.
Clearly, further investigation of the impact of
current smoking on coronary plaque progression,
assessed by serial IVUS, is warranted.*Philippe Giral, MD
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Ezetimibe and Atorvastatin on Coronary
Plaque Regression After PCI
PRECISE-IVUSWe read with great interest the letter by Dr. Giral and
colleagues commenting on our recent paper (1). First
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235of all, we all agree with the authors regarding the
adverse effects of smoking on cardiovascular disease
(CVD), recognizing the importance of campaigns for
smoking cessation as a preventable risk factor and
prevention of passive smoking in preventing CVD
(2). In addition, we recently demonstrated that
smokers showed more impaired peripheral
endothelial function than never smokers, resulting
in a higher rate of in-stent restenosis in smokers
(unpublished data). Furthermore, cigarette smoking
has been known as a major risk factor in the
development of atherosclerosis and has been shown
to cause inﬂammation and modiﬁcation of the lipid
proﬁle. These data seem to be theoretically
compatible with the association with cigarette
smoking and a higher burden of necrotic core in
coronary lesions observed by a cross-sectional
intravascular ultrasound (IVUS) study (3). Because
coronary plaque progression/regression has been
known as a multifactorial process, even in the
precisely designed serial IVUS studies, it appears to
be difﬁcult to show the direct relationship between
smoking and coronary plaque progression during a
relatively short study period.
Considering the varying ﬁndings of the previous
studies, the association between smoking status and
coronary plaque progression has still been contro-
versial. As the authors of letter noted, an appropri-
ately designed serial IVUS study evaluating the
impact of smoking on coronary plaque progression
primarily is deﬁnitely warranted.*Kenichi Tsujita, MD, PhD
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Transcatheter Aortic
Valve Replacement
With Balloon-Expandable
Versus Self-Expandable ValvesCHOICE Trial ResultsWe read with interest the paper by Abdel-Wahab et al.
(1) on 1-year outcomes of the CHOICE (Randomized
Comparison of Transcatheter Heart Valves in High
Risk Patients With Severe Aortic Stenosis: Medtronic
CoreValve Versus Edwards SAPIEN XT Trial)
randomized clinical trial comparing transcatheter
aortic valve replacement (TAVR) with the balloon-
expandable (BE) Edwards SAPIEN XT valve (Edwards
Lifesciences, Irvine, California) versus self-
expandable (SE) Medtronic CoreValve (Medtronic,
Minneapolis, Minnesota). Of interest, the authors
concluded that mortality was not statistically
different between the 2 groups, but there were
numerically higher stroke rates with BE valves. These
data are interesting, but we suggest some caution in
their interpretation. Indeed, important differences
are present in the baseline characteristics between
the 2 groups. First, signiﬁcantly more women have
been enrolled in the SE group. Of note, several
studies (2,3) and a recently published meta-analysis
(4) showed that mortality after TAVR is signiﬁcantly
lower in women compared with men. Second,
patients in the BE group tended to be older
(2.3 years older) and with a reduced left ventricular
ejection fraction compared with SE patients, and
both variables are important predictors of mortality
after TAVR.
